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INTRODUCTION 
 
Overview of cancer in the head and neck region 
 
Head and neck cancer (HNC) is the sixth most common cancer with about 650.000 new cases and 
estimated 350.000 cancer deaths worldwide every year.8;43 Squamous cell carcinomas (SCC) are 
found in 90% of all HNC. HNC is a heterogeneous type of cancer and shows great variations among 
gender, age and ethnic groups. The international classification of diseases (ICD) promotes 
international comparability in collection, classification and presentation of incidence and mortality 
statistics. In a global perspective the incidence of HNC in Norway is low and constituted 690 of 
25.577 (2.7%) of all new cancers in 2006. The distribution of locations of new cases in Norway in 
2006 is shown in Table 1 (data from The Norwegian Cancer Registry) according to the ICD-O.  
 
Table 1. Cancers in Norway in 2006 
 
Locations 
 
New cases 
Incidence rates per 100.000  
(age adjusted) 
ICD-O codes Males Females Total Males Females Total 
C00-C96 All cancers 13410 12167 25577 343,5 288,9 310,9 
C00 Lip 68 46 114 1,6 1,0 1,2 
C01-C02 Tongue 47 39 86 1,2 0,9 1,1 
C03-C06 Oral cavity 63 61 124 1,7 1,4 1,6 
C07-C08 Salivary glands 17 32 49 0,4 0,8 0,6 
C09 Tonsils 47 18 65 1,4 0,5 1,0 
C10-C14 Naso,- oro-, hypopharynx 54 23 77 1,6 0,7 1,1 
C30-31 Nasal cavity, sinus 24 23 47 0,6 0,6 0,6 
C32 Larynx 116 12 128 3,2 0,3 1,7 
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Oropharynx and the tonsillar region 
 
The oropharynx includes 4 areas: 
• The base of the tongue 
• The tonsillar area (tonsillar fossa and tonsillar pillars) 
• The soft palate  
• The portion of the pharyngeal wall between the pharyngoepiglottic fold and the 
nasopharynx. 
 
Figure 1 and 2. Basic anatomical structures in the oropharynx and the tonsillar region.98  
 
 
 
 
 
The palatine tonsil  
The palatine tonsil is an almond-shaped mass of largely lymphoid tissue embedded in a fibrous 
capsule. It is situated in the triangular fossa between the diverging palatopharyngeal and palatoglossal 
folds (the tonsillar pillars). The medial portion of the tonsil is free and projects into the oropharynx. 
Laterally the floor of the tonsil is formed by the pharyngobasilar fascia deep to which, in the upper part 
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of the fossa are the superior constrictor muscles and below is the styloglossus muscle. The superior 
part of the tonsil is separated from the base of the uvula by a fold of mucous membrane from the 
palatopharyngeal arch. The inferior portion of the fossa is the glossopalatine sulcus.  
 
Structure of the tonsil 
The tonsil consists of a mass of lymphoid follicles in a connective tissue framework. The epithelial 
lining is a non-keratinizing stratified columnar epithelium. In the centre of each nodule, the germinal 
centre, the lymphocytes are less packed and here the multiplication of the lymphocytes takes place. The 
medial surface of the tonsil constitutes 15-20 openings irregularly spaced over the surface. These 
openings leading to deep, narrow, blinded recesses are termed the tonsillar crypts. The crypts 
distinguish it from other lymphoid organs because they may penetrate almost the whole thickness of 
the tonsil. The lateral part of the tonsil is not covered by a mucous membrane, but a fibrous capsule 
separating the tonsil from the wall of the oropharynx by loose areolar tissue. After tonsillectomy the 
whole tonsillar fossa is lined by stratified epithelium. 
 
Nerve and blood supply  
The tonsillar branch of the glossopharyngeal nerve is the main sensory nerve supply. The upper part of 
the tonsil is supplied by the lesser palatine nerves, branches of the maxillary division of the trigeminal 
nerve. Sympathetic fibres reach the tonsil on arteries supplying it and come from the superior cervical 
ganglion. The main artery is the tonsillar branch of the facial artery. Further arterial supply is from the 
lingual artery and the greater palatine vessels from the maxillary artery. The venous drainage is to the 
paratonsillar veins and vessels passing to the pharyngeal plexus or facial vein. 
 
Lymphatic drainage 
Lymphatic vessels pass to the upper deep cervical group of nodes, particularly the jugulodigastric 
group situated just below the posterior belly of the digastric muscle. 
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Histopathology and staging 
 
SCC are the most common of tonsillar neoplasms (94%), while malignant lymphomas account for 
about 5% of tonsillar malignancies. Plasmacytomas, sarcomas and other rare tumors may occur in the 
tonsillar area. SCC may be classified by degree of differentiation into well-, moderately- and poorly-
differentiated types.  
 
Figure 3. Tonsil with SCC 
 
 
In larger tumors (> T1) it may be difficult to discriminate between an origin in the tonsillar fossa 
versus an origin in the tonsillar pillars or the rest of the oropharynx. Therefore our series included all 
C09 locations (or the ICD-7 locations 145.0-145.9 as coded in the Norwegian Cancer Registry). 
Tumors of the tonsillar fossa are either exophytic or ulcerative and are generally present in a more 
advanced stage than are tumors of the tonsillar pillars. Lesions involving the anterior tonsillar pillar 
may appear as areas of dysplasia, inflammation or exophytic lesions and they often ulcerate. 
Germinal centre 
Crypts 
Tumor 
Tumor 
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Epidemiology and risk factors  
 
The incidence of cancer at the base of the tongue and the tonsils has increased worldwide, especially in 
males and age less than 45 years.38 The increase in incidence of tonsillar cancer over decades in 
Norway is shown in Table 2 (data from the Norwegian Cancer Registry) and males have the most 
marked increase in incidence.  
  
Table 2. Incidence of tonsillar cancer in Norway in three different time periods  
(only palatine tonsil, ICD-O: C09.9) 
 
 
New cases 
Incidence rates per 100.000  
(age adjusted) 
 Males Females Total Males Females Total 
1960-1984 242 93 335 0.3 0.1 0.2 
1985-1996 224 87 311 0.7 0.2 0.4 
1997-2006 306 102 408 1.0 0.3 0.6 
 
Social inequalities are related to the risk of HNC. Individuals with low education, low social class or 
low income have an odds ratio (OR) of 1.8-2.4 for developing HNC compared to others.40 HNC has 
been strongly linked to chronic tobacco and alcohol abuse. Tobacco consumption as a risk factor for 
HNC was recently reported in a metaanalysis of 10 studies. For current smokers the OR was 7.60 
Involuntary smoking (passive smoking) is also associated with an increased risk for HNC, with an OR 
of 1.6 after exposure of more than 15 years at home.60 Frequent alcohol consumption increases the risk 
of cancers of the oropharynx.77 More than 350 g of alcohol per week with an OR of 2.6 and 11-20 
cigarettes per day (OR 2.4) were dose-dependent risk factors. The results showed a tendency for 
women to have a greater risk (OR 1.8) than men at any given level of tobacco consumption.151  
Quitting tobacco or alcohol use has been reported to reduce the HNC risk in several studies. In 
a large metaanalysis, persons who quit tobacco smoking for 1-4 years had a cancer risk reduction (OR 
0.7) compared with current smokers. Smoking cessation for 20 years or more gave a further risk 
reduction reaching the level of never smokers (OR 0.2). For alcohol use a beneficial effect on the risk 
of HNC was only observed after >20 years of quitting (OR 0.6 compared with current drinking), 
reaching the level of never drinkers. These results support that cessation of tobacco smoking and 
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cessation of alcohol drinking protect against the development of HNC.120 Tobacco chewing is 
associated with higher risk for HNC. Betel quid is carcinogenic for the oral cavity and hypopharynx.43  
About 15-20% of HNC occurs in non-smokers and non-drinkers, suggesting the presence of 
other risk factors.63 In Japan tooth loss as a result of poor oral hygiene, has been found to be associated 
with higher risk for HNC.86 In a case control study of 132 patients with oral and oropharyngeal SCC in 
Sweden, oral hygiene, dental status, alcohol and tobacco use and human papilloma virus (HPV) 
infection were risk factors for developing cancer. Individuals who have a low body mass index also 
have an increased risk of HNC. This may be explained by increased effects of carcinogens in patients 
with low body mass index.139 Diet has a role for developing HNC, and an inverse association exist 
between total fruit and vegetable intake and the risk of HNC.43   
HPV is a member of the papilloma virus family capable of infecting humans and causing 
cancer.182 HPV establishes productive infections only in the mucous membranes covered by squamous 
epithelium of the skin. A minority of the nearly 200 known types of HPV leads to cancers. HPV is thus 
subdivided into two main groups, the high risk and the low risk viruses, referring to their ability to 
cause cancer. In the high risk group HPV-16 is the most common type found in tonsillar carcinomas 
(TC).170  
An association between HPV and oral carcinomas was first reported in 1983,169 and in 1989 
HPV-16 DNA was reported to be present in TC.24 Gillison et al presented in 2000 a series of 253 
squamous cell carcinomas of head and neck (SCCHN), where 25% were HPV-positive. The HPV-
positivity at the three most frequent sites were oropharynx; 57%, oral cavity; 12% and hypopharynx 
10%.63 Mork et al published in 2001 an important case-control study (292 SCCHN compared to 1568 
matched controls) from a joint Nordic cohort where it was shown that HPV exposure preceded 
development of clinical disease. HPV-16 seropositive patients had an increased risk of subsequent 
oropharyngeal cancer (OR 2.2). Tumor tissue analyses in 160 of these patients revealed that 50% of 
oropharyngeal- and 16% of oral SCC contained HPV-16.129 In a Swedish study 3/320 healthy controls 
had HPV high risk DNA in mouthwash or tonsillar fossa.74 Dahlstrøm et al found that “never smokers” 
and “never drinkers” with HNC most frequent were women, and more than half the “never smokers” 
and “never drinkers” patients with an oropharyngeal primary were serologically positive for HPV-16.47  
HPV-positive TC have been found significantly less often among tobacco smokers and/or tobacco 
chewers than in non-smokers and/or non-chewers.84 In a case-control study oral HPV infection was 
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strongly associated with oropharyngeal cancer among subjects with or without the established risk 
factors of tobacco and alcohol use.45  
In a review published in 2004 of 432 patients (27 patient series) with TC, 51% were HPV-
positive, with HPV-16 being the most prevalent subtype (84%).170 The worldwide geographical 
variations of HPV-positivity in TC are great. In Taiwan only 13% of TC cancer were found to be HPV-
positive,36 in Hong Kong 29% (1985-2004) and in Australia 46% (1990-2001).113 During the period 
1986-2007, 43% of Greek TC patients had HPV in their tumors.150 In Middle Germany for the period 
1996-2005 76% of the TC were HPV-positive.65 The highest HPV prevalence in TC in the world is 
reported from Sweden. In the county of Stockholm, 93% of TC were HPV-positive in the period 2006-
2007.130  
The estimates of HPV prevalence vary with the locations of tumors within the head and neck 
region, and tumors in the tonsillar region have a remarkably higher viral load compared to carcinomas 
at other sites.35 Hobbs et al systematically reviewed studies that tested for HPV-16 exposure in 
anatomically defined sites in the head and neck and in a control group. The association between HPV-
16 and cancer was strongest for tonsil (OR 15.1), intermediate for oropharynx (OR 4.3) and weakest 
for oral (OR 2.0) and larynx (OR 2.0). Less than 5% of laryngeal carcinomas are HPV-positive.87  The 
causal role of HPV in sino-nasal SCC is also emerging.171 In summary, HPV is a well established risk 
factor for cervical-, anogenital cancer and HNC. The relation between HPV and vaginal-, vulvar-, 
penile-, skin-, oesophageal-, stomach-, lung-, breast-, bladder- and prostate cancer is not yet completely 
resolved.158;182 
The HNC type showing the most consistent worldwide association with Epstein-Barr virus 
(EBV) is the undifferentiated form of nasopharyngeal carcinoma (UNPC). UNPC is characterized by 
the presence of undifferentiated carcinoma cells together with a prominent lymphocytic infiltrate, the 
latter is believed to be important for the growth of the tumor cells. A link between EBV and UNPC 
was suggested as early as 1966 based on serological studies.181 However, EBV does not seem to be an 
important risk factor in TC. In 46 TC patients with T2N2bM0, EBV was only found in one case.37 
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Pathogenesis, phenotypic and genotypic aberrations in HNC  
 
SCCHN originate from keratinized epithelial cells of the mucous lining. In Figure 4 a progression 
model for SCCHN developed by several works is shown.8;29;138 Differences between normal 
epithelium and malignant cells of SCCHN are results of specific alterations in genes controlling 
deoxyribonucleic acid (DNA) repair, proliferation, apoptosis, invasion and angiogenesis. These 
changes are results of oncogene activation or tumor suppressor gene inactivation resulting from 
interaction with known risk factors in SCCHN carcinogenesis.  
 
Figure 4. A progression model for SCCHN carcinogenesis.8 
  
 
One of the most common events is inactivation of the TP53 suppressor gene which is found in about 
50% of SCCHN. The TP53 gene is localized to chromosome region 17p13.1, encoding for the p53 
protein which is directly involved in the regulation of the cell cycle. Loss of function of TP53 is 
common in human cancers, and inactivation of the TP53 gene via mutations during tumorigenesis may 
result in inappropriate progression through the cell cycle after DNA damage, thus resulting in survival 
of cells that otherwise might have been destined to die. Accumulation of p53 which most often results 
from mutations is associated with metastatic disease or poor prognosis in several cancer types. 
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The p16 gene is a tumor suppressor gene involved in cell cycle control. Inactivation of p16 is 
an early detectable change in SCCHN and leads to cellular proliferation and development of cancer.166 
Furthermore, loss of chromosome region 9p21 is found in 70-80% of SCCHN. Telomerase assists in 
telomere maintenance and immortalisation, and is reactivated in 90% of SCCHN.122 Prognosis for 
patients with telomerase-negative tumors is worse than for those with telomerase-positive tumors.104 
MicroRNA is a class of post-transcriptional regulators. They are nucleotide RNA sequences that bind 
to complementary sequences in target mRNAs, usually resulting in their silencing. The contribution of 
microRNAs to carcinogenesis in SCCHN seems clear, and a study of 169 SCCHN showed that 
alterations in microRNA expression were related to exposures such as causal alcohol consumption.9 In 
187 patients with SCCHN, amplification of the MYC gene, which is an oncogene, was associated with 
tumor progression.18  
Epidermal growth factor receptor (EGFR) is central to SCCHN biology. EGFR can trigger 
pathways that regulate cell proliferation, apoptosis, metastatic potential and angiogenesis. Increased 
EGFR expression is seen in 90% of SCCHN.8 The process of new blood vessel formation, 
angiogenesis, is fundamental for the growth of tumors and development of metastasis. Angiogenesis is 
regulated by many factors; the most important are vascular endothelial growth factor (VEGF) and its 
receptors. In a study of 85 TC a significant inverse relationship between EGFR and HPV status was 
found.56 VEGF and EGFR were risk factors for local recurrence and disease-specific death in 
univariate analyses, but the associations weakened after adjustment for HPV. Among patients treated 
with radiotherapy, VEGF was associated with disease-specific death after adjusting for HPV and TNM 
stage. Patients with tumors positive for EGFR and high levels of VEGF expression had a worse 
prognosis compared to all other groups combined after adjusting for HPV and TNM stage.56 In 82 
patients with SCCHN, HPV status correlated inversely with EGFR expression. EGFR overexpression 
was a negative prognostic factor regardless of HPV status, and HPV status was a prognostic factor for 
progression and survival.100 In 135 oral SCC patients EGFR was not correlated to prognosis, in 
contrast to p53 and p16.157 In 56 patients with oral and oropharyngeal carcinomas, VEGF was found to 
be a prognostic factor and VEGF positivity was associated with poor relapse-free and overall 
survival.164 
DNA aneuploidy means numerical or structural chromosomal abnormalities and nearly all solid 
tumors have aneuploid cell clones. During cellular division whole chromosomes or fractions of 
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chromosomes are lost, which may result in the formation of aneuploid cells. DNA aneuploidy is found 
in TC and is associated with worse prognosis.124 Chromosomal instability (CIN) implies that cancer 
cells loose or gain chromosomes or chromosomal material during mitosis representing an increased 
rate of change in the chromosomal structure,110 and is associated with aneuploidy. Some researchers 
claim that aneuploidy develops late in cancer and is not a cause of cancer, but in many studies CIN is 
regarded as one of the earliest steps in human carcinogenesis112;161 and is also found in HNC.174 When 
cells become aneuploid there is an uneven distribution of genomic DNA to daughter cells during 
mitosis. The mechanisms underlying chromosomal instability and the development of aneuploidy 
however are still unknown.121  
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The spindle assembly checkpoint 
 
 
The spindle assembly checkpoint (SAC) is a regulatory system that restrains progression through the 
metaphase-to-anaphase transition marked by sister chromatid separation. SAC delays anaphase until all 
sister chromatid pairs have become bipolarly attached. When the microtubulus attach to kinetochores 
(protein structures on chromosomes where the spindle fibres attach during division to pull the 
chromosomes apart), chromosomes are aligned on the metaphase plate and the SAC stopping 
mechanisms are removed. Thus the SAC can be seen as a house porter.  
Our work has focused on two important proteins of the spindle checkpoint, Mad2 (Mitotic 
arrest deficient 2, Mad2L1 is the official gene name) and BubR1 (Bubbing uninhibited by 
benzimidazole, Bub1B is the official gene name),92 which are activated by the lack of microtubule 
attachments to chromosomal kinetochores during metaphase.102 The genetic regions coding for Mad2 
and BubR1 are localized to the long arms of chromosome 4 (4q27) and chromosome 5 (5q14-21), 
respectively. BubR1 localizes to the kinetochores in early metaphase and prevents premature 
separation of sister chromatids. BubR1 also performs several roles during mitosis, mitotic timing and 
spindle function, but the interdependence of these functions is unclear.146 Defective BubR1 plays a role 
in the regulation of apoptosis and chromosomal instability.5;61   
Premature chromatide separation syndrome (PCS) is a rare autosomal recessive disorder 
characterized by premature separation of sister chromatids of all chromosomes.90 Children with PCS 
show several abnormalities, including a high risk of malignancy, such as Wilms tumor and 
rhabdomyosarcoma. In PCS cells show severe chromosomal instability not only because of the mitotic 
checkpoint defect, but also because of the centrosome amplification. BubR1 deficiency causes 
centrosome amplification as well as SAC defects. This implies a novel role of BubR1 in preventing 
centrosome reduplication in interphase cells.90 These findings are illustrated in Figure 5. 
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Figure 5. A model of some functions of BubR1.90 
 
 
Several reports suggest that aberrant mitotic SAC proteins may be an important cofactor in the 
development of CIN and cancer development.102 SAC defects and CIN were demonstrated in SCCHN 
in 2003,128 and these cancers harbour defects in other genomic loci critical in tumor development and 
SAC control such as p53.57 The role of BubR1 in HNC and its clinical significance is unclear. BubR1 
protein is suggested to be one of the contributing factors involved in the pathogenesis of oral SCC, and 
is a possible marker for human oral squamous cell carcinogenesis.89 
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Clinical aspects 
 
Patients with cancer in the oropharynx are often asymptomatic until their primary tumor reaches a 
significant size (T3, T4) or metastasizes to a lymph node in the neck (N+). The most common 
locations of cancer in the oropharynx are the tonsil and the anterior tonsillar pillar. Common presenting 
symptoms are ipsilateral referred otalgia, discomfort, dysphagia, sensation of a lump or foreign body in 
the throat, trismus, pain, tendency of aspiration or unpleasant odour. Biopsy of the primary tumor 
confirms the diagnosis. Suspected lymph nodes in the neck should be examined with cytological 
aspiration. In our patient series 65% had positive lymph nodes. The diagnosis of a positive lymph node 
was in the beginning of this study period based on clinical findings, since cytological aspiration was 
not an established method at that time. Distant metastases are seldom detected at diagnosis (2% in our 
population), but a complete staging process includes examination for metastatic disease.   
 
Figure 6.  An ulcerative T1 TC arising from the right tonsillar fossa 
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Treatment 
 
Therapies available for the management of HNC include surgical resections, radiotherapy and 
chemotherapy. HNC has complex anatomic and physiologic relationships to the structures from which 
they arise. Multimodal management is required for advanced stage disease, while single modality 
treatment is usually sufficient for early lesions. Non-surgical therapies have been reevaluated in a 
metaanalysis of 6400 patients with oropharynx cancer (51 retrospective studies) who underwent (1) 
surgery with or without radiotherapy or (2) radiotherapy with or without neck dissection. The overall 
outcomes were the same, but the rate of severe complications was as high as 23% in the surgical 
subjects. The authors concluded that primary non-surgical treatment should be advocated.137 Increased 
use of radiation, systemic/targeted therapies and function-preserving surgical approaches have allowed 
for organ preservation without compromising outcomes in properly selected patients.107 
 
Radiotherapy 
The treatment strategies for TC have changed over the years. From 1960-2000 radiotherapy was the 
mainstay of treatment. In radiotherapy the total dose and fractionation are most important. In the early 
megavoltage years, the 1950s and 1960s, the recommended dose for the tonsillar region was 60 Gy. 
Later the total dose raised to 65-70 Gy.126;159 However, no clear time-dose relationship was apparent 
and research on dose-intensity emerged through the 1990s on the basis of the studies of Withers et 
al.176 The dose-intensity can be altered through accelerated and/or hyperfractionated radiotherapy.21 In 
accelerated regimens the total treatment time is reduced using 6 fractions per week. However, acute 
morbidity is significantly more intense with 6 than with 5 fractions per week.135 This 6-fractions-
weekly regimen has now become the standard treatment in HNC in Norway. In hyperfractionated 
radiotherapy two or three fractions are delivered each day (dose per fraction 1.1-1.5 Gy) to a higher 
total dose (76-81 Gy). In a metaanalysis of 15 trials with 5221 HNC patients, hyperfractionation had 
the greatest benefit with a 8% survival benefit at 5 years, while accelerated regimens without total dose 
reduction, had a 5-year survival benefit of 2% as compared to standard fractionation.21 Mostly for 
practical reasons, hyperfractionation in HNC is not routine in Norway today. 
Several studies have justified the role of radiotherapy as a primary treatment modality in early 
TC.32 In addition, salvage surgery and neck dissections are important. The target for radiotherapy is the 
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primary tumor area and regional lymph nodes in the neck. The latter is included as a standard also 
when lymph node metastases are not diagnosed, due to the high risk of microscopic disease. For 
patients with involvement of lymph nodes in the neck, a neck dissection is usually performed 5-6 
weeks after radiotherapy. Often these lymph nodes show no residual tumor after concomitant 
chemoradiotherapy.118 The necessity of performing neck dissection after adequate radiotherapy has not 
been assessed in randomized clinical trials.  
 
Chemoradiotherapy 
The treatment paradigm for locally advanced HNC has evolved over the last decade as the role of 
chemotherapy has been substantiated by clinical trials. The superiority of cisplatin-based 
chemoradiotherapy in improving survival when compared with conventional radiotherapy alone in 
locally advanced SCC, has been documented in metaanalyses and clinical trials.16;141;142 Concomitant 
cisplatin seems to give a 5-year survival benefit of 8%. In Norway, concomitant cisplatin-based 
chemoradiotherapy (one weekly dose of cisplatin up to 6 times) is now standard treatment for patients 
with unresectable disease (stage III and IV). The addition of a taxane in induction chemotherapy may 
improve efficacy over cisplatin and 5-FU,178 but has not yet become a standard therapy.142  
 
Elderly patients 
The percentage of elderly people with HNC is rising due to increasing average lifespan. As with 
younger patients, elderly patients require a multidisciplinary approach in order to optimise treatment 
results. The biological- and not the chronological age should be defined individually based on co-
morbidities and performance status. The different treatment modalities for HNC have been reported to 
be well tolerated by the elderly patients.22 However, as discussed later, comorbidity and competing 
mortality are of increased importance in elderly patients. 
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New approaches in therapy 
Novel therapeutic approaches such as immunotherapy are under clinical investigation. Emerging forms 
of HNC immunotherapy involve both the use of monoclonal antibodies that target growth factor 
receptors where immune activation appears to contribute to tumor cell lysis, as well as various forms of 
active vaccination strategies which activate and direct the patients cellular immunity against the 
tumor.49  
Anti-EGFR monoclonal antibodies, either as single agents or associated with chemotherapy, 
have been shown to be active and only slightly toxic.8 Among them, cetuximab has proven to be the 
most promising. Cetuximab is an IgG1 monoclonal antibody against the ligand binding domain of 
EGFR. It enhances the cytotoxic effect of radiation in SCCHN. Bonner et al showed that the addition 
of cetuximab to high dose radiotherapy increased the control of locoregional disease and survival in 
424 patients with stage III or stage IV SCC of the oropharynx, hypopharynx and larynx.20 As compared 
to cisplatin-based chemotherapy plus fluorouracil alone in a randomized study of 442 patients, 
cetuximab plus cisplatin–fluorouracil chemotherapy improved overall survival when given as first-line 
treatment in patients with recurrent or metastatic SCCHN.175 The question has been raised if cetuximab 
should replace cisplatin in HNC. However, a trial testing radiotherapy plus cetuximab versus 
radiotherapy plus cisplatin-based regimen has not been performed.153 
For patients with HNC tumor hypoxia is a potent predictor of adverse outcomes.133 Hypoxic 
cell radiosensitizer (nimorazole) given in association with conventional radiotherapy showed to be an 
important prognostic factor for locoregional control and survival in invasive carcinoma of the 
supraglottic larynx and pharynx.134 HNC that is both hypoxic and highly angiogenic has a poor 
prognosis even after chemoradiotherapy, and patients with substantial overexpression of VEGF have a 
two-fold higher risk of dying. EGFR is abnormally activated in epithelial cancers and radiation 
increases the expression of EGFR. EGFR signalling also stimulates angiogenesis, but via mechanisms 
independent of hypoxia. Inhibition of one pathway (e.g. EGFR) probably upregulates signalling of 
alternative pathways, e.g.VEGF.25 In a phase I/II study an EGFR inhibitor, erlotinib, was combined 
with an anti-VEGF antibody, bevacizumab, in patients with recurrent or metastatic SCCHN. Four of 48 
patients had complete responses.39  
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Prognosis 
 
The 5-year relative survival of patients with tonsillar cancer in Norway during three time periods is 
shown in Figure 7. Relative survival means survival rates that have been adjusted for other causes of 
death (competing mortality). As presented, the prognosis has improved significantly over the past 
decades in Norway. The largest difference is seen in patients with age < 60 (from 33% to 73%), while 
the 5-year relative survival for age > 60 increased from 18% to 37%.  
 
Figure 7. The 5-year relative survival (%) of patients with tonsillar cancer in Norway during three 
different time periods (ICD7: 145.0, ICD-O: C09.9) 
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Tumor-related prognostic factors 
The most used staging system for TC is Tumor Node Metastasis staging system (TNM), coordinated 
by the International Union Against Cancer (UICC). The TNM system was introduced in 1943, but it 
was not until 1977 that HNC was included in this staging system. The staging system describes the 
anatomic extent (spread) of cancer before treatment. It was designed to aid in treatment planning 
and evaluation, to ease the communication between different treatment centres and to give some 
indication of prognosis.83  
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The TNM classification of 1978 for oropharyngeal cancer was:75 
T0: No evidence of primary tumor 
T1: Tumor 2 cm or less in greatest dimension 
T2: Tumor more than 2 cm but no more than 4 cm in greatest dimension 
T3: Tumor more than 4 cm in greatest dimension 
T4: Tumor invades adjacent structures, e.g. through cortical bones, soft tissues of neck, deep muscles of tongue 
N0: No evidence of regional lymph node involvement 
N1: Evidence of involvement of movable homolateral regional lymph nodes 
N2: Evidence of involvement of movable contralateral regional lymph nodes or bilateral lymph nodes 
N3: Evidence of involvement of  fixed regional lymph nodes 
M0: No distant metastasis 
M1: Distant metastasis present 
 
In the revised TNM classification of 1989168 the definitions of N categories for oropharyngeal 
cancer were modified as follows: 
N0: No evidence of regional lymph node involvement 
N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension 
N2a: Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension  
N2b: Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension 
N2c: Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension  
N3: Metastasis in lymph nodes, more than 6 cm in greatest dimension 
 
In order to obtain a more balanced distribution of patients and thereby improve the prognostic 
information, several investigators have introduced new staging systems for HNC. These revised 
staging systems are all based on the established TNM system and do not deal with other variables. 
Hart and Berg regrouped TNM into 4 new stages generally relocating the patients toward more 
advanced stages.15;76  Jones and co-workers introduced TANIS consisting of 7 new categories 
obtained by adding the integer values of T and N yielding a total T+N sum ranging from 1-7.95 
These categories were further regrouped into three stages. Later Snyderman regrouped TANIS into 
4 stages.167 Hall and co-workers proposed a system with 5 new prognostic levels where the N stage 
was modified combining N1 and N2a into N limited and N2b, N2c and N3 into N extended.73  
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Patient-related prognostic factors 
The prognostic importance of the different patient variables has been explored in many patient 
series. A matched-pair analysis of race or ethnicity in outcomes of HNC patients receiving similar 
multidisciplinary care, showed no impact of race or ethnicity on survival.33 Older HNC patients 
seem to have worse prognosis than younger patients,94;106 but contrasting findings exist.71 The 
impact of gender on prognosis in HNC is more unclear. Competing mortality in HNC is correlated 
to several patients factors and is higher in females.123 In 226 and 1881 patients with SCC in the 
oropharynx, females have higher loco-regional control than males,14;114 but gender was not a 
significant predictor of survival.114 Hall et al did not find any prognostic importance of gender in 
637 HNC patients,73 and similar findings have been published for 81 TC patients70 and 289 HNC 
patients.93  
The performance status (Karnofsky, WHO, ECOG) allows patients to be classified 
according to their functional impairment. It can be used to compare effectiveness of different 
therapies and to assess the prognosis in individual patients.41;72;93 Unfortunately, this variable often 
has many missing registrations in medical records. In 270 HNC patients a pretreatment hematologic 
profile was found to be a useful prognostic marker in patients with HNC. Both monocytosis, anemia 
and thrombocytosis had cumulative, negative effect on the prognosis.34 A metaanalysis examined 
the evidence for an association between patient and/or provider-related diagnostic delay and late 
stage at diagnosis in 27 eligible studies. The relationship between diagnostic delay and stage at 
diagnosis varied in direction and magnitude, with no consistent positive association in any of the 
HNC sites.67  
In United States, patients with Medicaid/Medicare had shorter survival after a diagnosis of 
SCCHN when compared with patients with private insurance. 105 Comorbidity reduces the survival 
in HNC.4;106 A study of 1371 HNC patients found that comorbidity was present in 36.4% of the 
patients. Cardiovascular-, respiratory-, gastrointestinal comorbidity and diabetes showed a 
significant relationship with short-term mortality, which was 5.7%. Comorbidity impacts overall 
survival of newly diagnosed patients with SCCHN.48 In two studies of TC non-smokers had better 
survival.71;91 In HNC high alcohol consumption is associated with a higher risk of recurrence.152 
Death from non-cancer causes (competing mortality) is an important event in HNC.152 A study from 
the Netherlands of 479 patients with stage III to IV HNC included in prospective trials, showed that 
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the 5-year cumulative incidence of competing mortality was 19.6%. In multivariate analyses, 
competing mortality was associated with gender female, increasing age, increasing Charlson 
Comorbidity Index, decreasing body mass index and decreasing distance travelled to the treating 
centre.123 
 
Biological prognostic factors 
Exophytic growth of the primary tumor3 and lingual involvement of the primary tumor have shown 
to give prognostic information in TC.119 The importance of histopathological differentiation in 
prognosis is not clear. Bentzen and Bataini have showed that well-differentiated tumors are 
associated with lower tumor control.13;14 On the other hand, poorly differentiated TC are followed 
by poor survival.51;119 Underlying genetic abnormalities may explain the discordance between the 
clinical outcome and the TNM status or location.1;96 DNA aneuploidy is found in TC and is 
associated with worse prognosis.124 The possible prognostic implications of EGFR and VEGR have 
been discussed earlier in this introduction.  
 
Treatment-related prognostic factors 
The most important changes are summarized in Table 3 below.   
 
Table 3. Some important improvement in the treatment of HNC 
Year Author Treatment Study Stage Improvement  
  
1998 Overgaard134 Radiotherapy +/-  
nimoraxole  
Randomized, 
n=414 
I-IV  + 16%  
local control 
2000 Pignon141 Concomitant cisplatin Metaanalysis I-IV + 8%  
5-year survival 
2006 Bourhis21 Accelerated radiotherapy  
without total dose 
reduction 
Metaanalysis III-IV  + 2%   
5-year survival 
2006 Bourhis21 Hyperfractionated 
radiotherapy 
Metaanalysis III-IV  + 8%  
5-year survival 
2006 Bonner20 Radiotherapy +/-  
anti EGFR – Cetuximab 
Randomized, 
n=414 
III-IV + 20 months in  
median survival 
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AIMS OF THE STUDY 
 
In this study we wanted to answer the following questions: 
 
1. Are modified TNM-based classification systems better prognostic tools than the original 
TNM classification? 
 
2. Can new prognostic indices including patient and treatment variables based on multivariate 
survival analyses, give additional prognostic information compared to TNM alone? 
 
3. What is the prevalence of HPV subtypes in TC in Norwegian patients,  
and has it changed over the past decades? 
 
4. How does the presence of HPV correlate to clinical parameters, other markers and patient 
prognosis? 
 
5. Dysfunction of spindle checkpoint proteins may induce chromosomal instability/aneuploidy. 
What is the level of expression of the spindle checkpoint proteins Mad2 and BubR1 in TC? 
 
6. Can the expression of spindle checkpoint proteins serve as useful prognostic factors in TC?  
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PATIENTS  
 
Series 1 - Prognostic indices, n=310 
 
From 1960 until 1996 310 consecutively untreated patients with SCC of the tonsillar region without 
metastatic disease were admitted to the Norwegian Radium Hospital and/or the  
Department of Otolaryngology, the National Hospital in Oslo. The tumors were retrospectively 
staged according to the 4th edition (1978) of the TNM system.75  Mean age of patients was 63 years 
and the male/female ratio 4/1. Most patients presented with advanced disease at the time of 
diagnosis, 59% had lesions staged T3-T4 and 65% had regional (N1-N3) metastases.  
Tumor tissue was fixed in formalin and embedded in paraffin. We were able to obtain 
adequate tumor tissue from original archival tissue blocks of biopsies and surgical specimens from 
199 of the 310 patients. Tissue sections were cut at 4 μm thickness and stained with hematoxylin-
eosin and reevaluated by an experienced pathologist (Prof. Ole Petter Fraas Clausen). The original 
diagnosis of SCC was confirmed for all patients. 
Complete follow-up and accurate cause of death were obtained by direct patient knowledge, 
review of outpatient and hospital charts, autopsy findings, direct contact with local hospitals, family 
physicians or in some cases by next of kin. The mean follow-up was 40 months. At the time of 
survival analyses 28% (87/310) patients were still alive. In the survival analyses event was defined 
as death due to the tonsillar carcinoma (47%), fatal complications during treatment (1%) or deaths 
of unknown causes (13%). Patients dying of other diseases 7% (23/310) or other head and neck 
cancers 4% (12/310) were treated as censored observations (under risk until death). Patient 
treatments are summarized in Table 4. 
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Table 4. Treatment in 310 patients with TC 1960-1996 
Treatment  n=310 % 
Surgery                   resection primary tumor 
neck dissection 
87 
97 
28 
32 
Radiotherapy        No                          
< 50 Gy 
50 - 59 Gy  
50 - 69 Gy 
70+ Gy 
8 
46 
46 
78 
130 
3 
15 
15 
25 
42 
Chemotherapy       No 
Yes1 
237 
73 
76 
23 
 
1 16 patients received cisplatin-based chemotherapy (not concomitant) 1983-1996.  
 
Series 2 - HPV, n=137 
 
Adequate tumor tissue from original archival tissue blocks of biopsies and surgical specimens was 
obtained for 199 of the 310 patients. It was possible to isolate good quality DNA from 137 of the 
199 tissue specimens, which defined the study population.    
Series 3 - The spindle checkpoint proteins, n=105 
 
From patients in series 2 we were able to measure spindle checkpoint proteins in 105 patients from 
which there was sufficient tumor tissue left in the paraffin blocks. 
 
 
Patient selection and variation in therapy 
 
Patient selection can represent an important bias in studies of markers and prognosis. This study 
was designed to reduce the patient selection to a minimum as all the consecutive patients of the two 
cooperating hospitals were reviewed. Both hospitals’ files were checked, thus the chance of missing 
some patients was very unlikely. Sixteen patients were excluded from further evaluations. Eleven of 
them received no treatment because of either poor general condition or treatment refusal. Five 
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patients had disseminated disease at the time of diagnosis. With minimal selection within the 
hospitals we included 310 M0 patients who were treated with the intention to cure, which represent 
the world’s second largest series of TC. In the same period 811 patients with ICD 145 were 
recorded in the Norwegian Cancer Registry, implying that our hospital series constituted about 40% 
of the whole country. Adjusted for the population our hospitals served, this indicates no selection of 
importance on the national level. 
 
Table 5. Age, gender and stages in the two period 
Variables Period 
 1960-84 
n=148 
1985-96 
n=162 
Agegroup n % 95% CI n % 95% CI 
  < 60 44 30 23-38 79 49 41-56 
  60+ 104 70 62-77 83 51 44-59 
Gender       
  Males 112 76 68-82 120 74 67-83 
  Females 36 24 18-32 42 26 20-33 
Stage       
  I 5 3 1-8 9 6 3-10 
  II 16 11 7-17 22 14 9-20 
  III 49 33 26-41 36 22 16-29 
  IV 78 53 45-61 95 58 51-66 
 
 
In order to obtain a large patient series and thus a higher statistical power, the inclusion period was 
as long as 37 years, from 1960 to1996. Due to this long period, heterogeneity in staging and 
treatment can be confounding variables. New diagnostic modalities can result in stage “migration”, 
which means that patients could have been classified into higher stages after for example computer 
tomography came into use. Computer tomography made it easier to visualize the extension of the 
primary and secondary tumors and to detect regional metastases earlier and have systematically been 
used since 1985.  
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However, the stage distribution did not change significantly for the two time-periods before 
and after 1985 (Table 5), and thus the use of computer tomography scans does not seem to have 
contributed to important stage migration. Table 5 also shows that the patients were significantly 
younger in the last period. Furthermore, a uniform use of protocols, procedures and close 
cooperation between the two hospitals should hopefully have reduced stage migration to a 
minimum.  
The patients did not receive a uniform treatment, and we have explored this consideration in 
several ways. For example, chemotherapy was a significant variable in the univariate survival 
analyses, but not in the multivariate analyses. Even when chemotherapy was “forced into” a Cox 
model, the regression coefficients for the other variables were not notably changed, which indicates 
that there was no prognostic implication associated with the use of chemotherapy. This is supported 
by a multicenter study of Lewin and co-workers including 460 patients with HNC.111 They found no 
survival benefits for patients treated with neoadjuvant chemotherapy.  
Surgical parameters were not among the significant prognostic variables in this study. 
Lymph node dissection performed for regional metastases was tested and did not influence the 
survival. This may be due to the fact that the patients with regional metastases received adequate 
preoperative radiation therapy (no residual tumor tissue was histologically detected in 57% of the 
patients) and that the number of patients with advanced regional disease were relatively few. Local 
surgery was performed for diagnostic and therapeutic purposes, but this parameter was not tested in 
the survival analyses.  
The two most significant treatment factors in this study were the total dose and the duration 
of radiotherapy. The standard total radiation dose since the 1980’s has been 70 Gy and we selected 
70 Gy and 50 days as cut-offs.  We adjusted for these two variables in Paper 1 by including them in 
the prognostic indices derived and tested. In Paper 2 and 3 total dose and duration of radiotherapy 
were tested in the multivariate analyses together with HPV and BubR1, but did not emerge as 
significant factors. Thus the reported prognostic importance of HPV and BubR1 should not have 
been influenced by differences in radiotherapy regimens.   
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METHODS AND METHOLOGICAL CONSIDERATIONS 
 
Tissue sampling and preparation 
 
In this retrospective study fresh frozen material was not available and the analyses had to be 
performed on paraffin embedded tissue blocks. A recent study of formalin fixed cervical specimens 
back to 1931, showed that high quality DNA was extracted and successfully used for detection of 
HPV and sequencing.17 We were able to obtain adequate material from original tissue blocks from 
199 of the 310 patients. However, a previous study of telomerase expression consumed some of 
these tissue blocks.  
In Table 6 below the distribution of some variables (age, gender, stage and period) for these 
199 patients compared to the other 111 patients are shown. The 95% confidence intervals of the 
percentages did overlap, indicating no selection of importance. Similarly, no selection bias was 
found for the 137 patients where DNA was isolated when comparing with the other 173 patients 
without isolated DNA (data not shown). Also for the 105 patients included in the spindle protein 
study, no selection bias was found for age, gender, stage or period (data not shown). 
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Table 6. The distribution of some variables for 199 patients with tissue available  
compared to the other 111 patients   
Variables Tissue available 
 No 
n=111 
Yes 
n=199 
Agegroup n % 95% CI n % 95% CI 
  < 60 42 38 29-48 81 41 34-45 
  60+ 69 62 52-71 118 59 52-66 
Gender       
  Males 81 73 64-81 151 76 69-82 
  Females 30 27 19-36 48 24 18-31 
Stage       
  I 1 1 0-5 13 7 4-11 
  II 16 14 8-22 22 11 7-16 
  III 32 29 21-38 53 27 21-33 
  IV 62 56 46-65 111 56 49-63 
Period       
1960-84 58 52 43-61 90 45 38-51 
1985-96 53 48 39-57 109 55 48-62 
 
 
Tissue microarrays  
 
The use of whole sections of paraffin-embedded tissues is time-consuming in studies including 
many tissue sections. The tissue microarrays technique (TMA) for examining a large number of 
histological sections simultaneously was established in 1998.101 Core needle biopsies from paraffin-
embedded tissue blocks from many patients are arrayed in one new paraffin block. The analyses of 
one or a few master slides make it possible to study the entire cohort of tissue blocks from many 
different patients. 
Our study included many specimens, but whole sections were used for Ki-67 and p53 
analyses since TMA was not established in our laboratory at the time these analyses were 
performed. BubR1 and Mad2 analyses were performed later when the TMA technique was 
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established.27 The most representative tumor areas were marked on the tissue blocks prior to tissue 
core sampling. Two or three tissue cores each 1,0 mm in diameter were sampled from these areas.  
The advantages of TMA are that it is time-saving, many specimens are processed under the 
same conditions, the amount of archival tissue required is less and the costs are reduced due to 
lower amount of antibodies needed. A possible pitfall utilizing the TMA technique is that tissue 
cores are not representative of a tumor originally many cm in diameter, and may not represent the 
true distribution of protein expression within the tumor. However, the TMA has been compared to 
whole sections in several studies, and the validation showed good correlation between the two 
methods.88 In a study of breast carcinomas antigen expression analyzed by immunohistochemistry 
(IHC) in 2-10 tissue cores were compared with antigen expression in whole sections, revealing that 
two tissue cores were comparable to a whole section in 95% of cases.30 However, the 
representativity of antigens in tissue cores depends on the distribution of the antigen expression in a 
tissue. In our experience the uneven distribution of p53 in a tissue, makes tissue cores less suitable 
for p53 analysis and we therefore examined p53 in whole tissue sections. The distribution of BubR1 
and Mad2 was relatively even so we assumed that 2-3 tissue cores from an area of representative 
tumor tissue gave representative results. Tissue loss or damage is another disadvantage of the TMA 
method. Old tissue blocks have a tendency to get fragile producing cracks, but this did not represent 
a major problem in our TMA sampling.  
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Changes in fixation protocols in the two periods and possible implications 
 
There was a change in fixation protocols in the study period from unbuffered to buffered 
formaldehyde. These changes may have altered the detection of protein expression and the quality 
of DNA. The most important molecular changes induced by formaldehyde are the formation of 
hydroxymetylene bridges between proteins and between proteins and nucleic acids. These bridges 
mask the antigenic epitopes by altering the structure of the proteins.  
In the HPV analyses we did not examine antigens, but there is a possibility that changes in 
fixation protocols have influenced the results. The change from unbuffered to buffered 
formaldehyde occurred at different times in the different laboratories. We examined tissue blocks 
from many pathology departments and have no information about when they changed the fixation 
technique. Due to this lack of information it is impossible to examine the effect of the different 
fixation protocols in this study.  
When we analyzed the distributions of p53, Ki-67, BubR1 and Mad2  in the two time 
periods, we found a modest left-sided displacement of the distributions (histograms), and lower 
mean and median in the oldest period only for Ki-67. However, the patterns (histograms) are much 
the same in both periods. Because of these similarities in distribution patterns and minor differences 
in mean and median values, we consider material from both time periods to be suitable for 
immunohistochemical analysis with the chosen antibodies. 
 
Table 7. Mean and median values p53, Ki-67, BubR1 and Mad in the two periods   
 
 
Variable 
1960-84 
n=60 
1985-96 
n=44-45 
 Mean Median Mean Median 
p53 42 29 45 41 
Ki67 49 50 63 (p=0.001) 63 (p=0.001) 
BubR1 17 12 20 18 
Mad2 29 27 33 28 
 
The distributions for the two periods are shown on the next page.  
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Figure 8 a: Some parameters 1960-84: 
 
 
 
 
 
     
 
Figure 8 b: Some parameters 1985-96: 
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Immunohistochemistry of BubR1, Mad2, Ki-67 and p53 
 
 
IHC refers to the process of localizing antigens (e.g. proteins) in cells of a tissue section by using 
antibodies binding specifically to epitopes in biological tissues. It is widely used in the pathology 
for diagnostic and prognostic purposes and in basic research to study the distribution and 
localization of specific proteins.  
There are two strategies for IHC detection of antigens in tissues, a direct method and an 
indirect method. We utilized the indirect method, which is a two step procedure that had been 
established earlier in our group.26 In the first layer an unlabeled primary antibody reacts with the 
tissue antigen and in the second layer the labelled secondary antibody reacts with the primary 
antibody. The second antibody coupled with streptavidin-horseradish peroxidase reacts with 
diaminobenzidine producing a brown staining where the primary and secondary antibodies are 
attached. Antigen detection can be significantly improved by treatment with an antigen retrieval e.g. 
citrate buffer, Tris-EDTA buffer and microwave treatment. Protein cross-links formed by formalin 
fixation may hide antigenic sites and are broken by antigen retrieval agents. 
The protocols and antibodies against BubR1 and Mad2 used in Paper 3 have been described 
previously.26 The specificity of the antibodies used is documented in previous publications and 
Western analyses verified that lysates from tumors showed protein bands at molecular weights 
consistent with those previously reported for these proteins.26 The expression of Mad2 was found in 
the nucleus and BubR1 in the cytoplasma in normal tissue.26  In tumor tissue there is some 
additional expression of Mad2 in the cytoplasm and some additional expression of BubR1 in the 
nucleus. The percentage of double expression was very low and was not registered. In this study 
positivity for Mad2 refers to the nucleus and positivity for BubR1 refers to the cytoplasm. 
The IHC for Ki-67 and p53 detection has been described in Paper 2. The Ki-67 antibody was 
a pool of two mouse monoclonal antibodies (MIB1 and MIB3 mixed supernatants, 1:50 dilution) 
kindly provided by Dr J Gerdes, Germany. The p53 antibody used was a mouse monoclonal 
antibody BP.53-12, 1:100 dilution, Novocastra Laboratories Ltd., Newcastle upon Tyne, UK). The 
same staining procedure was used for both antibodies. Three hundred tumor cell nuclei were 
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counted in randomly selected areas from whole tumor sections. The nuclei were scored as either 
positive or negative and the percentage of positive tumor cell nuclei calculated. TMA for Ki-67 and 
p53 analyses would therefore not give additional information to the results already obtained. 
False positive and negative results are always to be considered when using 
immunohistochemical techniques. It is therefore necessary to validate the antibodies used, either by 
Western blot analysis to see if they precipitate with protein bands of the expected molecular weight, 
or to use more than one antibody that shows similar results. The validity of the BubR1 and Mad2 
antibodies has been documented in previous publications from our group,26 and the validity of the 
Ki-67 and p53 antibodies has been documented in many previous publications from our and many 
other groups. We always use positive and negative controls for staining.  
The Ki-67 antigen was originally identified in the early 1980s, by use of a mouse 
monoclonal antibody against a nuclear antigen from a Hodgkin’s lymphoma-derived cell line. This 
protein was named after the researchers’ location, Ki for Kiel University, Germany, with the 67 
label referring to the clone number on the plate.62 The Ki-67 antigen is encoded by a gene on 
chromosome 10. Ki-67 expression varies throughout the different phases of the cell cycle. Cells 
express the antigen during G1, S, G2, and M phases, but not during the resting phase G0. Ki-67 
levels are low in G1 and S phases and rise to their peak levels in mitosis. Later in the mitotic phase 
(anaphase and telophase), a sharp decrease in Ki-67 levels occurs. Thus Ki-67 can be a reliable 
index of cellular proliferation. Ki-67 expression is related to prognosis in some cancers, such as 
breast-,180 lung,-162 bladder-179 and laryngeal cancer.154 
 p53 plays a sentinel role in the pathways that prevent development of cancer by inducing 
apoptosis, DNA repair and cell-cycle arrest in response to different types of cellular stress. The 
majority of head and neck tumors harbour mutations affecting the TP53 gene. Loss of function of 
p53 is common in human cancers, and inactivation of the TP53 gene via mutations during 
tumorigenesis may result in inappropriate progression through the cell cycle after DNA damage, 
thus resulting in survival of cells that otherwise might have been destined to die. Accumulation of 
p53 which most often results from mutations, is associated with metastatic disease or poor 
prognosis in several cancer types, such as HNC,166 oral carcinomas,157 lung cancer,44 colorectal 
cancer136 and breast cancer.12          
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Polymerase chain reaction, sequencing and blasting  
 
HPV is a single circular double stranded genome of ca 8 000 base pairs. In all the different HPV 
types the genome is organized similarly. It encodes for 6 early (E) and two late (L) genes. The 
transcription of viral DNA is regulated by early phase genes, while the capsid proteins involved in 
the viral spread, are regulated by late phase genes. E1-E2 proteins are required for DNA replication. 
E4-E5 proteins are needed for amplification of the viral genome. E6-E7 proteins of high-risk HPV 
induce cellular immortalization by regulating the functions of p53, p31 and pRb, pivotal proteins 
involved in apoptosis, DNA repair and cell cycle control.  
Polymerase chain reaction (PCR) used for HPV detection serves as a technique to amplify a 
single or a few copies of a DNA sequence, thus generating thousands to millions of copies. The 
HPV detection protocol has been described in detail in Paper 2. Short; the first step was to confirm 
the presence and quality of DNA by targeting -globin as a constitutive control, using PCO3/PCO4 
as specific primers. Following amplification on a PCR cycler, a process where cycles of repeated 
heating (denaturation) and cooling (renaturation), enable the DNA polymerase to copy the target 
DNA. For evaluation, the products were run on an agarose gel alongside a DNA ladder, a molecular 
weight marker containing DNA fragments of known size. The size of the bands (or fragments) 
indicating the specificity of the PCR products are determined relative to the DNA ladder. Samples 
with representative bands indicative of good quality DNA were subjected to further (HPV) analyses.  
General HPV detection was performed by using the universal HPV primers GP5+ and GP6+ 
and using a touchdown PCR protocol. Touchdown PCR is a variant of PCR that aims to reduce non-
specific background by gradually lowering the temperature of the PCR cycles. A high initial 
annealing temperature specifies the targets for subsequent amplifications at lower temperatures. The 
resulting products were run on an agarose gel and positive bands indicated HPV DNA.  
After excision from gel, the PCR products were purified using MicroSpin Columns S-300 
HR (Amersham Pharmacia Biotech) according to the manufactures instructions, and then sequenced 
with ABI PRISM BigDye Terminator Cycle Sequencing and run on an ABI 3130 XL sequencer. 
DNA sequencing determines the order of the 4 nucleotide bases adenine, guanine, cytosine and 
thymine in a DNA molecule. It results in a succession of bases representing the primary structure of 
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a DNA molecule or a strand. The key principle is the use of dideoxynucleotides as DNA chain 
terminators. The 4 nucleotides are labelled with fluorescent dyes of different wave length and the 
data output is fluorescent peak trace chromatograms. 
The results were analyzed using the NCBI Blast program 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). Basic Local Alignment Search Tool (BLAST) compares a 
query sequence with a database of sequences, identifying the origin (or source) of the sequence in 
question. The NBCI blasting program was utilized due to prior experience. In order to reduce the 
possibility of false positive and negative results the blasting process was repeated utilizing a second 
blasting program, Biology Workbench. The results from the two different blasting programs showed 
good correlation.  
Many detection methods have been used to study the role of HPV virus including in situ 
hybridization (ISH), IHC, Southern Blotting and PCR. ISH technique employs the use of HPV type-
specific radioactively labelled DNA oligonucleotides as probes complementary to various HPV 
DNA type sequences. This method is now considered the best method for HPV detection due to its 
high sensitivity and is the method of choice today. IHC have low sensitivity because it can only 
detect virus present in more than 10 copies of viral DNA pr cell. Southern blotting combines 
electrophoresis separated DNA fragments and fragment detection by probe hybridization, requiring 
a significant amount of DNA and is therefore less sensitive than PCR.63   
We used PCR for HPV detection because PCR was a common method for HPV detection at 
the time this study was initiated enabling us to compare our results with other studies.63;130;170 Other 
reasons were that PCR has a high sensitivity and our laboratory had good experience in utilizing 
PCR methods.23   
However, several have called for more standardised approaches to HPV testing in HNC.23;149 
Different methods are used to detect HPV; HPV DNA, HPV RNA, HPV proteins and cellular 
proteins. These have variable analytic sensitivity and specificity, and may have given false positive 
and false negative diagnosis of HPV in oropharyngeal carcinomas. Some argue that detection of 
high risk HPV by consensus PCR alone seems to be insufficient to accurately classify tumors.149  
Studies of cervical carcinomas have indicated that any single method or technique for the detection 
of HPV may underestimate the true prevalence of HPV.10 Two new diagnostic algorithms have 
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emerged. The first advocates screening for p16 by IHC followed by detection of HPV DNA by ISH. 
The second recommends detection of p16 followed by consensus PCR.149;163   
General primers for HPV were used in this study because of their ability to identify many 
different human HPV types simultaneously and thereby reduce the time taken to perform the 
analyses. Specific primers require many PCR repetitions which might increase the risk of 
contamination. In designing pairs or multiple sets of primers to participate in the same reactions, 
complementarity should be avoided to reduce formation of primer-dimers. Primer-dimers reduce the 
availability of the specific primers to participate in the polymerase driven reactions and thereby 
reducing the efficiency in the amplification process. Excessive DNA fragments in the form of 
primer-dimers are easily distinguished from the HPV bands due to significant differences in 
molecular weight. 
A disadvantage of the general primers is the relatively large size of the PCR fragment 
especially in samples that yield poorly amplifiable DNA as in formalin-fixed paraffin embedded 
material.99 The sensitivity is also influenced by the temperature of the PCR cycles. High 
temperature decreases the sensitivity which might cause loss of some of the relevant HPV 
genotypes. The general primers have been modified over time and the primers in use today can 
detect a wider range of mucosal HPV compared to the primers applied in this study. This presents 
other challenges. It is not hard to contemplate that if a patient has multiple infections with various 
genotypes, these are amplified in an unpredictable way as the PCR reaction favours the targets being 
closest to the primers in complementarity being represented in the highest quantity. Further, if 
several genotypes are being amplified simultaneously, this will jeopardise the sequencing reaction 
because of the multiplicity of targets. We believe these considerations have influenced on our 
results concerning the detection degree and the HPV genotype representation of the investigated 
samples. This is supported by other studies. In a study of cervical cancer samples comparing the 
general primers GP5+/GP6+ with the MY09/MY11 primer set, the MY-PCR detected 14 of 30 
(90%) samples  with multiple HPV types, whereas the GP+PCR detected 14 of 30 (47%) samples 
with  multiple HPV types.144 In the same study each primer set amplified some HPV types better 
than others causing biases in sensitivity. GP+PCR detected fewer samples containing HPV types 
52,53 and 61 compared to MY-PCR, but the predominant HPV types found in patients with cervical 
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cancer (HPV 16, 18, 32 and 45) was detected with equal frequency by both PCR systems.  Another 
reason for reduced sensitivity towards certain HPV types can be the circulation of a variant with 
additional sequence mismatch over the primer binding site.31  
The amplification potential of PCR makes it vulnerable for contamination by targeting  
spurious DNA products.23 Contamination with extraneous DNA is addressed with laboratory 
protocols and procedures that separate pre-PCR mixtures from potential DNA contaminants. Our 
use of separate rooms for PCR-setups, careful handling of the tissue blocks utilizing a new sterile 
scalpel and new gloves for each block, disposable plastic-ware and thoroughly cleaning the work 
surface between reaction setups reduce contamination. Contamination was monitored running 
negative controls. False positive signals can also occur due to self-priming of DNA because 
fragmented DNA caused by formalin fixation can act as primers.81  
The sequencing is today automated due to its great speed and dye terminator sequencing is 
the mainstay. The limitations of dye terminator sequencing include dye effect due to differences in 
in-cooperation of the dye labelled chain terminator into the DNA fragments, resulting in unequal 
peak heights and shapes in the chromatogram.2 
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Statistical analyses 
 
 
Survival analyses take into account both the event recorded (relapse or death) and the time to the 
event. Observations which are censored (the event has not occurred at the time of the study analysis) 
are included in the risk calculations until time of censoring. The Kaplan-Meier method gives a good 
graphical presentation of a survival curve,97 while the log rank test is a significance test of the 
differences between survival curves.140 Clinical research often involves several variables with a 
need for relative adjustment of their impact.85 Three main regression models are available. Multiple 
regression can be used for analyses of variations in a continuous variable (e.g. age), logistic 
regression for a binary response (event, no event) and Cox regression for survival (both event and 
time to event). 
Calculating survival curves in univariate survival analyses and the significance testing of the 
differences between the survival plots have few pitfalls. The most important concern is the problem 
of repeated analyses.155 We solved this in two ways in univariate survival analyses. First, we tested 
earlier reported thresholds if relevant. Second, we divided continuous variables such as Ki-67 into 
quartiles by using the 25%, 50% and 75% percentiles as cut-off levels, and thus did not search for 
“suitable” thresholds. Another advantage utilizing quartiles is the ability to identify U-effects (if 
high or low values of a continuous variable are associated with bad prognosis). p53 was not used as 
a continuous variable in survival analysis. The co-authors have previously used 5% cut off for colon 
cancer which correlated with the mutations present. We assumed it was suitable to have a higher cut 
off for ENT cancer since publications at that time indicated less accordance with p53 accumulation 
and mutations in ENT cancers. We also assumed that a few tumors with <10% positivity had 
mutations. Thus we chose 10% as a threshold since this value was commonly used by others. The 
median as a threshold value for BubR1 expression has previously been evaluated by Burum 
Auensen et al.28 Screening by quartiles did not show that other threshold values were more relevant 
than the median of BubR1 expression. 
The form of the candidate variables and the procedures used in stepwise testing in Cox 
regression can greatly influence which variables will remain in then “final model” (“significant” or 
“not significant”). Thus, a shortcoming of modern survival regression is that their extended use 
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implies a risk of introducing false negative as well as false positive prognostic factors in the medical 
literature.82 One way to solve this when the patient series is large enough, is to both derive and 
validate new prognostic indices in the same patient series as we did in the first paper. The problem 
of many repeated analyses in the Cox-analyses was also handled by a simplified approach (few 
analyses) where e.g. the focused factor (HPV or BubR1 expression) was tested against the 
established variables (TNM, age and gender).  
The prognostic indices were estimated by multiplying the regression coefficient with the 
group value associated with adverse survival for each variable. The higher the index, the worse was 
the survival. In the first paper we divided the prognostic scores into three groups: low-risk (the 
lowest 25% of the index-distribution), medium risk (2nd and 3rd quartiles) and high risk (the highest 
25% of the index-distribution). To make calculation of prognostic indices as simple as possible, we 
recoded all variables so the low risk values (i.e. females, HPV-positive, age < 60, high BubR1 
expression) were the reference group, coded as 0.   
The Cox regression model is based one main assumption, the proportional hazards (death 
risks).53;173 The model assumes that the relative death risk or hazard ratio (HR) for  patients in for 
example two age groups ( < 60 versus > 60) is the same (constant) at different times from start of 
the observation. We tested this assumption with plots. In Paper 3 this violation was visually so 
large, that we recoded TNM stage I-II to be the reference group (coded 0). This was in contrast to 
the other papers where TNM stage I was the reference group and stage II-III were grouped together.  
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SUMMARY OF RESULTS 
 
 
Paper 1: Different prognostic indices in 310 patients with TC 
 
Several modifications of the TNM system have been reported to be better prognostic tools than the 
original classification in HNC, but none of these modifications had been tested in a large series of 
TC.  
The 5 reported TNM-based stage modifications were all highly significant predictors of 
survival in our 310 patients. The patients were randomly divided into a derivation group (n=199) 
and a validation group (n=111). In univariate survival analyses of the derivation group, 7 patient- 
and treatment variables were significant prognostic factors (p< 0.05). In multivariate survival 
analyses of the derivation group, 4 host- and treatment variables that indicated shorter disease 
specific survival were identified; age > 60, gender male, total radiation dose < 70 Gy and duration 
of radiotherapy > 50 days. We then created two sets of prognostic indices based on pretreatment 
data (TNM + age group + gender) and a treatment index (TNM + age group + gender + radiation 
dose + duration of radiotherapy).  
When applying these indices to the validation group, all 4 indices separated the patients into 
different risk groups of high statistical significance (p< 0.001). By adding the two host variables or 
the two treatment variables, the prognostication improved for TNM. The TNM stages were 
distributed in the different risk groups based on the pretreatment index. For example, of 63 patients 
in TNM stage IV, 6 came in low risk-, 18 in medium risk- and 39 were in high-risk groups. By 
adding the treatment variables into the prognostic indices, the differences between the survival 
curves increased, indicating an even better prognostication and a further shift in distribution 
between the risk groups were noticed.    
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Paper 2: Human papillomavirus (HPV)-positive TC are frequent and have a favourable 
prognosis in males in Norway 
 
The objective of this study was to determine the prevalence of HPV subtypes in TC in Norwegian 
patients, and to correlate the presence of HPV to clinical parameters and prognosis. Furthermore, we 
wanted to explore the significance of Ki-67 and p53 positivity and their individual relationships to 
HPV.  
Seventy-one (52%) of these specimens were HPV-positive, 56 males and 15 females. Age 
was significantly associated with HPV-positivity. Of patients younger than 60 years, 62% were 
HPV-positive compared to 43% of patients 60 years or older (p<0.05). HPV-positivity was 
significantly more frequent (64%) in the latter period 1985-1996 of the patient series compared to 
38% in the first period 1960-1984 (p<0.01). p53 positivity was recorded in 71% of the patients. The 
distribution of HPV-positivity versus negativity was not statistically significantly different for 
gender, stage, T- and N categories, p53 positivity or Ki-67 expression. The HPV-16 subtype was 
most predominant, found in 62 of 71 (87%) positive tumors.   
HPV-positive patients survived longer than HPV-negative patients (p< 0.05), with a 5-year 
survival of 54% for HPV-positive versus 33% for HPV-negative tumors. When stratifying the HPV 
survival analyses for gender, a more favourable survival was found only for HPV-positive men 
(p<0.01), whereas HPV-positive and HPV-negative females had overlapping survival curves. p53 
positivity or high Ki-67 index did not correlate with survival. The unadjusted HR for HPV-negative 
patients (versus positive) was 1.6 (95% CI: 1.01-2.5). 
In multivariate, stepwise analyses where HPV was tested against known prognostic factors, 
HPV-positivity was found to be a significant prognostic factor in addition to stage, age group and 
gender (p < 0.05). The HR for HPV-negative patients was 1.6 (95% CI: 1.01-2.6) when adjusting 
for period, stage, age group and gender. 
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Paper 3: Reduced expression of the spindle checkpoint protein BubR1 correlates with bad 
prognosis in TC 
 
Spindle assembly checkpoint proteins such as Mad2 and BubR1 are important for normal mitosis. 
The aim of the present study was to examine their expression in TC, their possible impact on 
prognosis and correlation to clinical variables, the prevalence of HPV, p53 status and Ki-67 
positivity in 105 patients. 
BubR1 and Mad2 were both expressed in TC. The median numbers of positive tumor cells 
were 16% and 27%, respectively, for BubR1 and Mad2. BubR1 expression was mainly cytoplasmic, 
whereas Mad2 expression was mainly nuclear. No significant correlations were seen between 
BubR1 and Mad2 expression, and no significant relationships between each protein and clinical 
data, HPV status or p53 accumulation were found. HPV status was not correlated to levels of 
BubR1 expression. BubR1 expression was significantly correlated with Ki-67 positivity (r=0.4, 
p<0.01), whereas Mad2 expression was not.  
A significantly reduced survival was found for patients with tumors having low expression 
of BubR1, with a 5-year survival of 25%, whereas a 5-year survival of 60% was seen for patients 
with tumors having high BubR1 expression (p<0.01). Analyzing the survival for BubR1 according 
to quartiles, did not reveal significant trends when comparing the 4 groups. BubR1 expression 
showed significantly different survival in age groups < 60 or > 60, in males, in stage III and stage 
IV, in HPV-negative patients and in p53 positive patients. The unadjusted HR for low BubR1 
expression was 2.2 (95% CI: 1.3-3.7). 
In multivariate, stepwise analyses where BubR1 was tested against known prognostic 
factors, BubR1 expression was a significant prognostic factor in addition to stage, age group and 
HPV status (p < 0.05). The HR for patients with low BubR1 expression was 2.0 (95% CI: 1.1-3.7), 
adjusted for period, stage, age group, gender and HPV status. 
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DISCUSSION 
 
Prognostic factors 
 
 
The TNM system is primarily a staging system and it is regularly revised. These revisions are partly 
based on prognostic information from different sources. The main purpose of the TNM system is to 
have robust and reliable staging definitions over time. This makes it easier to describe and compare 
patient populations over decades, between countries and institutions and gives adequate frames in 
controlled studies.83  
In order to develop a better assessment of prognosis at least two options exist. The TNM 
system can either be modified between the official international revisions, or we can maintain the 
current, virgin TNM classification and add new variables to it. Regression models such as the Cox 
regression model designed for time-to-event analyses have for a long time been available in user-
friendly statistical software. The regression models give regression coefficients which are estimates 
for the relative death risk. These can as shown in Paper 1 and 2, be used relatively easily to develop 
practical prognostic indices for clinicians. 
In Paper 1 we showed that the TNM stages and the 5 earlier reported TNM-based stage 
modifications were all highly significant prognostic factors in this large series of TC. Although two 
of the TNM modifications seemed to be better, it was not possible to declare a sure winner 
compared to the virgin TNM. However, a simple pretreatment prognostic index which added gender 
and age to the TNM classification defined especially high-risk patients very well (Figure 2a, Paper 
1). In order to intensify the treatment and follow-up for high-risk patients, tools to identify these 
patients with high precision are mandatory. Tests and reports of modifications of the TNM system 
are useful inputs to the next revision of the TNM. However, with the aim to predict prognosis even 
more optimally, our data and indices support the strategy to add new and perhaps simple prognostic 
factors to the virgin TNM.83  
We identified 4 important prognostic factors: age, gender, total radiation dose and duration 
of radiotherapy. A separation in pretreatment and treatment-based indices gave complementary 
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information about the risk groups. We believe it may be useful to separate indices based on 
pretreatment information and indices based on information available after the initial therapy has 
been completed. The treatment based factors are here referred to as prognostic factors, in contrast to 
predictive factors which describe the responsiveness of a particular tumor to a specific treatment 
and determine which treatment is best.116 These indices may be useful for clinicians by giving 
information about the need for additional therapy. The two most significant treatment factors in this 
study were the total dose and the duration of radiotherapy. Our finding of the importance of a total 
dose of 70 Gy is in accordance with current international treatment programs.127 The implication of 
shorter duration of radiotherapy is now realized in accelerated or hyperfractionated radiotherapy 
regimens.21 Bentzen and Thames also found treatment time to be of prognostic value.14;172  
Many papers have presented different possibilities to regroup the staging system in order to 
obtain more homogenous stages and to yield better prognostic information.117 One of the criticisms 
against the established TNM classification for HNC has been that stage IV includes too many 
patients compared to the other stages. Our data showed that the distribution of patients between the 
different stages is more even in the reported stage modifications compared to the original TNM 
system. On the other hand, the TNM stage system is well established internationally, and in our 
opinion TNM should only be changed if it results in a major prognostic improvement which cannot 
be achieved with other adjustments.  
In Paper 3 we found an association between low BubR1 expression and poor prognosis. This 
implies that we have generated a new hypothesis regarding prognosis which has to be validated in 
other series. However, if we are able to collect large patient series as we did in Paper 1, we can 
divide the material randomly into two groups, a derivation group and a validation group and present 
validated indices. This approach has several advantages. It is less time consuming and confounding 
factors may be reduced since it uses the same patient series, the same data collection and the same 
management. 
An alternative had been to include period in the multivariate analyses in all three papers. In 
Paper 1 it was not done as the main purpose was to derive and validate a prognostic index using 
standard variables and to validate different TNM classifications with our data. Furthermore, the 
regression analyses in Paper 2 and 3 were based on the findings from Paper 1 (the pretreatment 
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variables TNM, age and gender. I Paper 2 HPV-negative patients had an unadjusted HR of 1.6. 
When period (1960-84 versus 1985-96) also was included and adjusted for, HPV status obtained 
only a minor change in HR to 1.5, while period had a HR of 1.6. The HR for HPV-negative patients 
was 1.6 when adjusting for period, stage, age group and gender. In Paper 3 patients with low BubR1 
expression had unadjusted HR of 2.2. The HR for BubR1 remained high, 1.8 adjusted for period, 
the latter had a HR of 2.0. BubR1 remained significant with a HR of 2.0 after adjusting for period, 
stage, age, gender and HPV. This argue for a conclusion that the oldest period did not give 
significant noise in the data and analyses, and thus did not challenge the main findings that HPV 
and BubR1 were important prognostic factors in our study.  
 
HPV 
 
In our study 52% of patients with TC tested for HPV showed HPV-positive tumors. Our prevalence 
of 52% is similar to the value in a review of 432 patients comprising 27 series where 51% of TCs 
were HPV-positive.170 The HPV-16 subtype was predominant, found in 87% of positive tumors. It 
is well documented that HVP-16 is the most frequent subtype.170  
When we combine our findings with the data from the Norwegian Cancer Registry shown 
earlier in this thesis, we can summarize 5 important and related observations. 1: The incidence of 
tonsillar cancer in Norway has increased from 1960, especially in men. 2: The prevalence of HPV-
positive patients has increased in the period from 1960 to 1996. 3: HPV-positive patients have a 
lower age at diagnosis. 4: There is a marked improvement in relative survival in tonsillar cancer in 
Norway from 1960 to 2006, mostly for males and for patients < 60 years. 5: HPV-positive, male 
patients have a more favourable prognosis. 
HPV-positivity was significantly more frequent (64%) in the latter period 1985-1996 of the 
patient series compared to 38% in the first period 1960-1985 (p<0.01). In the county of Stockholm, 
the proportion of HPV-positive TC increased significantly both from 1970 to 2000 (p < 0.0001) as 
well from 2000 to 2007 (p < 0.01), with 68% HPV-positive cases in 2000-2002, 77% in 2003-2005 
and 93% in the period 2006-2007. The prevalence of HPV-positive tumors almost doubled within 
each decade between 1970 and 2007, in parallel with a decline of HPV-negative tumors. The 
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prevalence of HPV-positive cancers is still increasing in Stockholm, suggesting an epidemic of a 
virus-induced TC.130 Also in Greek patients with TC a tendency towards an increase in the 
proportion of HPV-positive tumors has been reported when comparing the percentage of HPV-
positive tumors collected between 1992-1998 with those collected between 2000-2007.150 These 
different findings are summarized below. 
 
Table 8. The prevalence of HPV-positive TC in some countries over decades 
 
Country 
 
Period 
Total 
n 
HPV 
% 
95%  
CI 
Norway 1960-1984 63 38 26 – 51 
Norway 1985-1996 74 64 52 – 74 
Greece 1996-2007 28 43 24 – 63 
Germany 1996-2005 29 76 56 – 90 
Sweden 2000-2002 47 68 53 – 81 
Sweden 2003-2005 52 77 63 – 87 
Sweden 2006-2007 46 93 82 – 99 
 
Thus, TC may represent medical history. Which other neoplasm has over a few decades (30-40 
years) nearly completely changed its etiology? Identical HPV-16 DNA has been found within three 
couples where the husband and wife developed TC within 12 months of each other, revealing the 
potential infectious nature of oropharyngeal cancer.6;69 There is strong evidence that this rapid 
increase in HPV-positive TC is due to changes in sexual behaviour.66 Husbands of patients with 
cervical cancer have a higher risk of TC.80 Sexual partners of patients with HPV infection develop a 
higher risk of HNC.132 An increased HPV risk of oropharyngeal cancer is found in patients with a 
high lifetime number of heterosexual partners, young age at first intercourse and a history of 
orogenital sex.165 In a hospital-based, case-control study of 100 patients with newly diagnosed 
oropharyngeal cancer and 200 control patients without cancer, a high lifetime number of vaginal-sex 
partners (26 or more) was associated with oropharyngeal cancer (OR 3.1), as was a high lifetime 
number of oral-sex partners (6 or more) (OR 3.4). The degree of association increased with the 
number of vaginal-sex and oral-sex partners.45 A support for a possible transmission of genital HPV 
to fingers have been found in a study from Sweden. Of 13 patients with a history of both cervical 
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and finger SCC, HPV-16 was found in 5 finger SCC in 7 patients with HPV-16 cervical SCC.58 
Based on a simple anatomical logic and the above findings, we propose that the increase in oral sex 
with subsequent HPV infection is the most important change in the risk picture explaining the 
increase in the TC incidence.  
In a meta-analysis of the effect of HPV status, the overall and disease free survival were 
significantly improved for patients with HPV-positive tumours. While the majority of studies (21 
studies) reported an improved prognosis, several studies reported no difference (9 studies) or worse 
outcome (3 studies). For these three groups of studies, evaluation of HPV prevalence by tumour site 
may have provided an explanation for the reported differences in outcome. Studies reporting a 
worse prognosis or no difference in outcome had a much higher prevalence of HPV-positive 
tumours overall compared to those reporting a favourable prognosis. One explanation for the high 
prevalence of HPV infection reported in these studies may be that the majority of the HPV-positive 
tumours carried either low-risk or uncharacterized HPV types.145 Further evidence for HPV as a 
strong and independent prognostic factor was recently reported in a retrospective analysis of a 
randomized trial with 721 patients with stage III and IV oropharyngeal carcinomas. The patients 
were classified in low, intermediate, or high risk groups  regarding survival based on four factors: 
HPV status, pack-years of tobacco smoking, tumor stage and nodal stage.7 
Most reports of HPV as a favourable prognostic factor have not discussed a possible gender 
difference. In 2003 Ritchie reported an association between gender and HPV status with respect to 
survival in 139 patients with carcinomas in the oral cavity and oropharynx. It was reported that 
HPV-positive males had better prognosis than HPV-negative males, whereas a similar difference 
was not found in females.147 However, only 8 females of the 139 patients in the study of Ritchie 
were HPV-positive, and the authors warned about generalizations of this possible gender difference 
due to low numbers. The study of Ritchie and ours are among the largest patient series presented 
with HPV analyses in TC, and indicate that other studies with less patients may not have detected 
this gender difference due to lack of statistical power. In our first study of all 310 patients, gender 
gave additional prognostic information to TNM stage and age. As our multivariate analyses also 
found both gender and HPV status to be independent predictors together with stage and age, there 
seems to be both a gender and a HPV effect on survival. As HPV vaccination may be a future tool 
to reduce the incidence of TC, later studies should carefully examine this possible gender difference 
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regarding the impact of HPV presence on prognosis. By pooling and reanalyzing the world’s 3-4 
largest published studies, the HPV and gender interaction in TC should be clarified.  
Why HPV-positive TC in general has a better clinical outcome than HPV-negative tumors is 
not known. There are several hypotheses to explain this difference. It may be related to better 
treatment effects of radiation and chemotherapy due to intact apoptotic capacity and to better 
immune response against HPV.54 HPV-positive cells may suffer from hypoxia and can be more 
easily induced to apoptosis. The genome of HPV-positive cancer cells may be less unstable. 50;171 
Another possibility is that a different signalling pathway may be affected associated with less 
aggressive behaviour. It is reasonable to assume that deregulation of relevant cellular signalling 
pathways differ between HPV-positive and HPV-negative TC, respectively, and that the 
deregulation of growth is associated with more aggressiveness in HPV-negative tumors109.  
An impact of the immune response on tumor development is supported by the report of  
increased prevalence of TC in patients with impaired immune systems. Our study is consistent with  
the hypothesis that therapeutic anti HPV-16 vaccines developed for cervical cancer may also be of  
benefit in the management of TC.46 As the mean time from HPV infection to cancer development  
is about 12 years, the prevalence of HPV induced TC will increase steadily in years to come. Thus 
prevention of this cancer can be both by vaccination programs in young age and education about  
the risk of oral sex and safer sexual behaviour. In addition, two questions should be answered: What 
information should be given and which actions should be taken in males where the female partner  
has received the diagnosis of a HPV-positive cervical cancer? And the opposite relation; what  
information should be given and which actions should be taken in women where the male partner  
has received the diagnosis of a HPV-positive TC?   
Shuman has given some specific recommendations as follows:160 
• To ensure that patients receive factual and accurate information, HPV should be discussed 
as a possible etiologic agent with all patients with oropharyngeal squamous cell carcinoma. 
• Patient factors and physician judgment should dictate the utility of discussing HPV in the 
setting of HNC presenting at other head and neck sites in which HPV is unlikely to be a 
causative factor. 
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• The transmissibility of HPV may be discussed at the discretion of physicians, acknowledging 
that other than standard barrier methods, there exists no convincing evidence that specific 
behavior modifications or sexual contact precautions are necessary. 
• The favorable prognosis of HPV-related neoplasms may be discussed with patients as is 
clinically appropriate, understanding that treatment is not currently adjusted based on this 
information, and other factors can significantly affect prognosis. 
• Physicians may discuss the belief that HPV vaccination theoretically might help prevent 
certain HNC despite the absence of conclusive evidence. 
 
Fei et al explored the relationships between VEGF, EGFR, HPV, response to radiotherapy and 
clinical outcome in 85 TC. There was a significant inverse relationship between EGFR and HPV 
status. VEGF and EGFR were risk factors for local recurrence and disease-specific death in 
univariate analyses, but the associations weakened after adjustment for HPV. Among patients 
treated with radiotherapy, VEGF was associated with disease-specific death after adjusting for HPV 
and TNM stage. High-VEGF-expressing tumors positive for EGFR had a worse prognosis than all 
other groups combined after adjusting for HPV and TNM stage. However, HPV was a stronger 
prognostic marker than VEGF and EGFR in TC.56 
The improved prognosis and treatment responses to chemotherapy and radiotherapy by 
HPV-positive tumors may suggest that HPV detection is required for better planning and to 
individualize patient treatment regimes.66 In a prospective study the association of tumor HPV 
status with therapeutic response and survival among 96 patients with stage III or IV SCCHN of the 
oropharynx or larynx was evaluated.55 All patients received two cycles of induction chemotherapy 
with intravenous paclitaxel and carboplatin followed by concomitant weekly intravenous paclitaxel 
and standard fractionation radiation therapy. HPV-positivity was found in 40% of the patients. 
Compared with patients with HPV-negative tumors, patients with HPV-positive tumors had higher 
response rates after induction chemotherapy (82% versus 55%, p = 0.01) and after 
chemoradiotherapy (84% versus 57%, p = 0.007). Patients with HPV-positive tumors had improved 
overall survival compared to those with HPV-negative tumors.55 We suggest that a randomized trial 
should be performed to test the hypothesis that HPV-positive patients with TC can receive less 
intensive treatment without loss of quality or duration of life.125 In Norway, routine detection of 
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HPV has not been done up to now due to the costs. HPV detection in TC should be included as a 
routine analysis according to recent guidelines in USA.131  
p53 positivity is correlated with mutations of the TP53 gene, resulting in nuclear 
accumulation of dysfunctional p53 proteins with longer half-lives. Other mechanisms however, may 
lead to non-mutational nuclear accumulation and stabilization of the p53 protein.42 Since the E6 
protein of HPV16-18 binds and degrades p53 protein, the p53 negative tumors represent a rather 
heterogeneous group with respect to p53 function. p53 negative tumors in the present study thus 
presumably include those with wild type p53 as well as those with p53 inactivation by HPV and 
those with nonsense mutations. In one study HPV-16 DNA was detected in 72% of 100 paraffin-
embedded tumor specimens, and 64% of the patients with cancer were seropositive for the HPV-16 
oncoprotein E6, E7, or both.45 Thus, the HPV-mediated p53 inactivation by E6 may be an early and 
transient event during tumorigenesis, with later reestablishment of p53 function. This may 
contribute to the contradictory results reported in the literature concerning associations between p53 
immunoreactivity, prognosis and HPV status within these tumors.  
p53 is a tumor suppressor protein important for cell cycle regulation. It is involved in 
apoptosis induction and is required for growth arrest following DNA damage. Ki-67 is a molecular 
marker of tumor growth fraction and of cellular proliferation. In a small study of 33 patients with 
oropharyngeal carcinomas (11 TC), HPV-positive tumors had higher Ki-67 and lower p53 staining 
scores compared with HPV-negative tumors.52 We did not find any significant correlations between 
HPV status and Ki-67 or p53 positivity respectively, in TC. Two other studies of 42 and 30 patients 
with HNC did not find any correlation between HPV status and p53 positivity,11;103 similar to the 
results from our study. Hafkamp et al also support our findings as they report no correlation 
between HPV status and Ki-67 and p53 expression.71 
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The spindle checkpoint proteins 
 
 
The mechanisms of the spindle assembly checkpoint are still not completely understood. A recent 
publication showed that BubR1 may have at least three different functions.90 The complexities 
warrant a more careful discussion and interpretation of our findings.   
BubR1 and Mad2 were both expressed in TC. No significant correlations were seen between 
BubR1 and Mad2 expression, or between each protein and clinical data, HPV status or p53 
accumulation. BubR1 expression was significantly correlated with Ki-67 positivity, whereas Mad2 
expression was not. The induction of p53 by mitotic checkpoint activation seems to be essential for 
protecting cells against the abnormal chromosomal ploidization induced by mitotic checkpoint 
failure.59 Furthermore, p53 activation in response to mitotic spindle damage requires signalling via 
BubR1 mediated phosphorylation.68 This suggests a cross-talk between the mitotic checkpoint and 
p53. We did not find any correlations between the levels of BubR1 and Mad2 expressions 
respectively, and p53 accumulation. However, low BubR1 expression was a more apparent 
prognostic factor within patients with p53 positive TC. This suggests that p53 dysfunction as 
indicated by p53 accumulation is of importance for the poor prognosis of tumors with low BubR1 
levels. This is consistent with the documented crosstalk between these two proteins for maintaining 
proper mitotic checkpoint function preventing CIN. 
We have shown that BubR1 expression is a significant prognostic factor in TC. Low BubR1 
expression was associated with poor survival and was a significant prognostic factor both in 
univariate- as well as in multivariate survival analyses. Stratified survival analyses of BubR1 
revealed significantly different survival times within TNM stages III and IV, illustrating that BubR1 
is a novel, robust prognostic marker in TC in addition to the existing ones.   
Correlations between BubR1 expression and prognosis have to date not been reported for 
many cancer types. In a series of 104 patients with bladder carcinomas studied by Yamamato et 
al,177 overexpression of BubR1 correlated with higher histological grade, tumor recurrence, disease 
progression and high cell proliferation. In a recent study of 117 resected pancreatic head 
adenocarcinomas, high BubR1 expression was shown to be an independent, adverse prognostic 
factor for survival.64 In 160 patients with ovarian cancer high BubR1 expression was associated 
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with shorter recurrence-free survival.108 A study of 70 oral SCC found that high BubR1 expression 
was associated with shorter survival and in contrast to our results, they also showed that HPV was 
more prevalent in samples with a high BubR1 expression.115   
In a study of 181 cases with gastric cancer, high BubR1 expression correlated with DNA 
aneuploidy, advanced stage and poor prognosis. The authors transfected gastric cancer cell lines 
with BubR1 to observe the significance of the change in BubR1 expression. Enforced expression of 
BubR1 resulted in changes to the ploidy patterns and high proliferation activity as measured by Ki-
67 expression. These clinical and in vitro data may indicate that high expression of BubR1 may be 
one causative factor for the induction of DNA aneuploidy and progression of gastric cancer.5 Our 
results also show a significant correlation between BubR1 expression and Ki-67 positivity in TC 
and a similar association has been previously demonstrated in ulcerative colitis associated27 as well 
as in sporadic colorectal cancers.28  
Rizzardi et al studied BubR1 expression in 49 patients with oral SCC. Tumors with 
overexpression of BUBR1 were associated with a less advanced pathologic stage and showed a 
tendency of longer survival periods which supports our findings.148 Thus so far our study is only one 
of two studies to find low BubR1 expression as a bad prognostic factor. This contrasting finding 
may have several explanations: The mechanisms behind BubR1 reduction and the ensuing 
interference with tumor growth may differ in various types of tissues and their respective neoplasms 
(SCC versus adenocarcinomas). In our material the expression of BubR1 seems to be higher than in 
other reported studies, which may indicate an increased disruption of BubR1 regulation. 
Furthermore, disruption of BubR1 function may be associated with increased as well as reduced 
amount of protein present.  
Under normal conditions BubR1 participates in preventing premature advance from 
metaphase to anaphase during mitosis and is activated when the spindle microtubules are not 
correctly aligned with the chromosomes in metaphase. DNA ploidy in HNC has been studied in 
several patient series,19 and TC have previously been shown to display a high frequency of 
aneuploidy.124 In a report published by Hass and collaborators,78 DNA aneuploidy was more 
frequently seen in advanced head and neck tumors and  lymph node metastases from oral 
carcinomas  mainly harboured aneuploid tumor clones.79 In a patient series of 66 cases with TC a 
high degree of aneuploidy was found in most tumors. HPV- positive tumors had a lower degree of 
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aneuploidy than HPV-negative tumors with a non-significant trend of worse survival associated 
with aneuploidy.124 These findings are consistent with an association between low BubR1 
expression and aneuploidy also in TC, and may explain the poor prognosis in these patients.  
A defective mitotic checkpoint has been proposed to contribute to chromosomal instability. 
In 39 clear-cell renal cancers and 36 normal kidneys, expression of spindle proteins were analyzed. 
Overexpression of BubR1 was significantly correlated with CIN and tumor grade. The authors 
concluded that BubR1 overexpression plays a role in cytogenetic and morphologic progression of 
clear-cell renal cancer.143 In a series of 19 patients with invasive ductal breast carcinoma, the status 
of chromosomal and intrachromosomal instability and the expression for two genes involved in the 
mitotic spindle checkpoint pathway, Bub1B and Mad2L1, were examined. All breast cancers 
demonstrated higher chromosomal instability rates in tumor samples than in controls. Bub1B 
mRNA levels, but not Mad2L1 levels, correlated with intrachromosomal instability.156 
Poor survival for patients with low BubR1 expression was more pronounced in HPV- 
negative patients, in p53 positive patients, in males and in TNM stage III-IV. However, in all non-
significant strata, patients with low BubR1 always had the least favourable survival plots. Stratified 
analyses as performed here, result in smaller numbers in the subgroups. This may have contributed 
to false, negative results regarding the survival differences of BubR1 expression within some strata. 
Later studies should therefore test the hypotheses generated in our study regarding different effects 
of BubR1 within gender, TNM stage, HPV status and p53 status. However, one possible 
explanation for the difference in survival of patients with tumors with low BubR1 expression within 
the HPV-negative group, may be that the pathogenetic pathways for HPV-positive and negative 
carcinomas respectively, are quite different and that BubR1 interacts differently within these 
pathways.   
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CONCLUSIONS 
 
 
TNM and prognostic indices 
 
Previously reported TNM-based stage modifications are all useful predictors of survival in TC. In 
addition, age, gender, total radiation dose and duration of radiotherapy were important prognostic 
factors. We propose that both patient-, biological- and treatment factors should be tested carefully 
when building new prognostic indices in TC. 
 
HPV   
 
This study confirms a high and increasing prevalence of HPV-positive TC (from 38% to 64%) in 
Norwegian patients. The survival of the HPV-positive group was significantly better only in males. 
In multivariate analyses HPV-positivity was found to be a significant prognostic factor in addition 
to age, gender and stage. 
 
BubR1  
 
We have shown that BubR1 expression is a novel and strong prognostic factor in TC, giving 
additional information to the TNM stage and other known prognostic factors. Low BubR1 
expression was correlated with poor prognosis. 
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FUTURE PERSPECTIVES 
 
 
The change in etiology of TC due to the increasing prevalence of HPV should be followed up with 
several actions.  
1: In Norway, routine detection of HPV has not been done up to now due to the costs. HPV 
detection in TC should be included as a routine analysis to follow a possible further increase in 
prevalence and to facilitate further research.  
2: By pooling and reanalyzing the world’s 3-4 largest published studies, the HPV and gender 
interaction in TC could be clarified and settled.  
3: A randomized trial should be performed to test the hypothesis that HPV-positive patients with TC 
can receive less intensive treatment without loss of quality or duration of life.  
4: Two questions should be answered: What information should be given and which actions should 
be taken in males where the female partner has received the diagnosis of a HPV-positive cervical 
cancer? And the opposite relation; what information should be given and which actions should be 
taken in women where the male partner has received the diagnosis of a HPV-positive TC?   
 
The spindle protein BubR1 has a high expression and strong impact on prognosis in TC. The 
expression and importance of spindle proteins in other HNC should therefore be examined. This 
may provide an essential contribution to understanding the biology of HNC in general. A broader 
investigation of the impact of spindle protein expression in HNC should also elucidate if TC with 
high HPV prevalence are outliers in the HNC family. BubR1 expression as a novel and strong 
prognostic factor in TC should be verified in other patient series. 
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